Insmed Incorporated (INSM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Insmed Incorporated (INSM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
INSM - Insmed Incorporated
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$213.11
DETAILS
HIGH:
$269.00
LOW:
$160.00
MEDIAN:
$213.50
CONSENSUS:
$213.11
UPSIDE:
100.59%
Stock News
Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus
Insmed NASDAQ: INSM Chair and CEO Will Lewis said the company remains confident in the launch trajectory of BRINSUPRI, despite investor concerns over discontinuation rates that followed the company's latest update. Speaking at a Bank of America healthcare conference, Lewis said the company intended to provide “anchor points” around what he described as “one of the strongest launches in recent years.
Insmed Incorporated (INSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Insmed Incorporated (INSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
INSM stock plunges 23% after Q1 sales miss estimates despite 230% revenue growth and strong Brinsupri uptake.
Insmed Incorporated (INSM) Q1 2026 Earnings Call Transcript
Insmed Incorporated (INSM) Q1 2026 Earnings Call Transcript
Insmed Tanks On Its Most Important Launch; Why Analysts Remain Bullish
Insmed stock tanked Thursday after its new lung drug, Brinsupri, missed elevated buy-side expectations, though beat sell-side views.
Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates
Insmed (INSM) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.9. This compares to a loss of $1.42 per share a year ago.
Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
— Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025— — ARIKAYCE ® (amikacin liposome inhalation suspension) Revenues of $98.1 Million for the First Quarter of 2026, Reflecting 6% Growth Over the First Quarter of 2025— —Company Reiterates 2026 BRINSUPRI Revenue Guidance of at Least $1 Billion and 2026 ARIKAYCE Revenue Guidance of $450 Million to $470 Million— — Phase 3b ENCORE Study of ARIKAYCE in Patients with MAC Lung Disease Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoints— —Phase 3 PALM-PAH Study of TPIP in Patients with PAH Initiated in April 2026— BRIDGEWATER, N.J., May 7, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis
— Insmed's Educational Initiative, Suspect Bronchiectasis (Suspect BE), Aims to Elevate Recognition and Diagnosis of Bronchiectasis and Encourage Conversations with a Pulmonologist — — Bronchiectasis Symptoms Often Overlap with COPD or Asthma and May Go Unrecognized for Years, Highlighting the Need to Look Deeper at Respiratory Symptoms — — TV Personality, Ty Pennington, Brings Visibility to the Chronic Lung Condition Through His Experience Caring for His Mother, Who is Living with Bronchiectasis — BRIDGEWATER, N.J., May 6, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced a collaboration with Emmy® Award–winning TV host, designer, and carpenter, Ty Pennington, to launch Suspect Bronchiectasis (Suspect BE).
Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026
—New Data in Non-Cystic Fibrosis Bronchiectasis Further Define Impact of BRINSUPRI ® on Respiratory Symptoms— —Findings from a Pharmacokinetic Study Continue to Support Further Evaluation of Treprostinil Palmitil Inhalation Powder Phase 3 Development Program— —Additionally, Insmed Provides Independent Research Grant to the American Thoracic Society for a Landmark Quality Initiative to Improve Diagnosis of Bronchiectasis across the U.S.— BRIDGEWATER, N.J., May 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will present six abstracts from across its respiratory portfolio and pipeline at the American Thoracic Society International Conference 2026 (ATS 2026), taking place May 17–20 in Orlando, Florida.
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed to Present at May 2026 Investor Conferences
BRIDGEWATER, N.J., April 30, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: BofA Securities 2026 Healthcare Conference in Las Vegas on Tuesday, May 12, 2026, at 1:40 p.m.
Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026
BRIDGEWATER, N.J., April 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its first-quarter 2026 financial results on Thursday, May 7, 2026.
GraniteShares Advisors LLC Invests $680,000 in Insmed, Inc. $INSM
GraniteShares Advisors LLC purchased a new position in shares of Insmed, Inc. (NASDAQ: INSM) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 3,905 shares of the biopharmaceutical company's stock, valued at approximately $680,000. A number of other large investors also recently
Asset Management One Co. Ltd. Purchases Shares of 80,887 Insmed, Inc. $INSM
Asset Management One Co. Ltd. acquired a new position in shares of Insmed, Inc. (NASDAQ: INSM) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 80,887 shares of the biopharmaceutical company's stock, valued at approximately $14,260,000. A number of other hedge
Mirae Asset Global Investments Co. Ltd. Acquires 69,410 Shares of Insmed, Inc. $INSM
Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Insmed, Inc. (NASDAQ: INSM) by 764.3% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 78,492 shares of the biopharmaceutical company's stock after acquiring an additional 69,410
Assetmark Inc. Acquires 4,438 Shares of Insmed, Inc. $INSM
Assetmark Inc. boosted its holdings in Insmed, Inc. (NASDAQ: INSM) by 12.6% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 39,732 shares of the biopharmaceutical company's stock after buying an additional 4,438 shares during the period. Assetmark Inc.'s
Here Are Friday’s Top Wall Street Analyst Research Calls: Autodesk, Delek US Holdings, Insmed, Nike, Nutanix, ServiceNow, Shake Shack, Southern Copper, Veeva Systems, and More
Pre-Market Stock Futures: The futures are trading mixed as we approach the end of one of the most volatile and wild trading weeks in recent memory. After starting the day lower on Thursday as mixed reports on the success of the ships passing through the Strait of Hormuz rolled in, stocks gained momentum as the... Here Are Friday's Top Wall Street Analyst Research Calls: Autodesk, Delek US Holdings, Insmed, Nike, Nutanix, ServiceNow, Shake Shack, Southern Copper, Veeva Systems, and More
Insmed Ends Brinsupri Development in Skin Disease Post Study Failure
INSM scraps Brinsupri for HS after phase IIb failure, with placebo outperforming treatment despite no safety issues.
Insmed discontinues development of skin condition drug after mid-stage study miss
Insmed said on Tuesday it would discontinue the development of its treatment for a chronic, inflammatory skin condition, after the drug failed a mid-stage trial.
Price Targets
Insmed price target lowered to $185 from $205 at Truist
$185.00
(was $116.56)
Truist Financial
Insmed price target lowered to $160 from $177 at Wells Fargo
$160.00
(was $105.00)
Wells Fargo
Insmed price target lowered to $226 from $230 at Guggenheim
$226.00
(was $105.00)
Vamil Divan
·
Guggenheim
Insmed price target raised to $230 from $227 at Guggenheim
$230.00
(was $146.74)
Guggenheim
Insmed price target raised to $216 from $212 at RBC Capital
$216.00
(was $151.14)
RBC Capital
Insmed initiated with an Outperform at Raymond James
$200.00
(was $155.80)
Raymond James
Insmed price target lowered to $202 from $206 at Mizuho
$202.00
(was $160.18)
Mizuho Securities
Insmed price target raised to $245 from $230 at H.C. Wainwright
$245.00
(was $147.60)
H.C. Wainwright
Insmed price target lowered to $204 from $211 at Mizuho
$204.00
(was $159.03)
Mizuho Securities
Insmed price target raised to $166 from $162 at Morgan Stanley
$166.00
(was $158.80)
Morgan Stanley
Insmed price target lowered to $208 from $234 at Wells Fargo
$208.00
(was $161.00)
Tiago Fauth
·
Wells Fargo
Insmed price target lowered to $205 from $212 at Stifel
$205.00
(was $159.88)
Stifel Nicolaus
Insmed price target lowered to $211 from $212 at Mizuho
$211.00
(was $151.11)
Graig Suvannavejh
·
Mizuho Securities
Insmed initiated with an Overweight at Barclays
$231.00
(was $162.64)
Eliana Merle
·
Barclays
Insmed initiated with a Buy at Roth Capital
$212.00
(was $160.39)
Roth Capital
Insmed price target raised to $200 from $197 at RBC Capital
$200.00
(was $163.51)
Leonid Timashev
·
RBC Capital
Truist on Insmed (INSM): Brinsupri Launch Outpacing Most Bullish Expectations
$205.00
(was $166.25)
Danielle Brill
·
Truist Financial
Insmed price target lowered to $157 from $158 at Morgan Stanley
$157.00
(was $176.00)
Maxwell Skor
·
Morgan Stanley
Insmed price target lowered to $215 from $223 at UBS
$215.00
(was $173.34)
UBS
Insmed assumed with a Buy at Truist
$202.00
(was $166.55)
Danielle Brill
·
Truist Financial